AU740749B2 - Method of treatment - Google Patents

Method of treatment Download PDF

Info

Publication number
AU740749B2
AU740749B2 AU46885/99A AU4688599A AU740749B2 AU 740749 B2 AU740749 B2 AU 740749B2 AU 46885/99 A AU46885/99 A AU 46885/99A AU 4688599 A AU4688599 A AU 4688599A AU 740749 B2 AU740749 B2 AU 740749B2
Authority
AU
Australia
Prior art keywords
paroxetine
core
deposit
use according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU46885/99A
Other languages
English (en)
Other versions
AU4688599A (en
Inventor
Martin X. Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU4688599A publication Critical patent/AU4688599A/en
Application granted granted Critical
Publication of AU740749B2 publication Critical patent/AU740749B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU46885/99A 1998-06-16 1999-06-16 Method of treatment Ceased AU740749B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9812941 1998-06-16
GBGB9812941.4A GB9812941D0 (en) 1998-06-16 1998-06-16 Method of treatment
PCT/US1999/013623 WO1999065491A1 (en) 1998-06-16 1999-06-16 Method of treatment

Publications (2)

Publication Number Publication Date
AU4688599A AU4688599A (en) 2000-01-05
AU740749B2 true AU740749B2 (en) 2001-11-15

Family

ID=10833832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46885/99A Ceased AU740749B2 (en) 1998-06-16 1999-06-16 Method of treatment

Country Status (20)

Country Link
EP (1) EP1087766A4 (bg)
JP (1) JP2002518330A (bg)
KR (1) KR20010052895A (bg)
CN (1) CN1305379A (bg)
AP (1) AP2000002002A0 (bg)
AU (1) AU740749B2 (bg)
BG (1) BG105127A (bg)
BR (1) BR9911150A (bg)
CA (1) CA2335236A1 (bg)
CZ (1) CZ20004698A3 (bg)
EA (1) EA003584B1 (bg)
GB (1) GB9812941D0 (bg)
HU (1) HUP0102507A3 (bg)
IL (1) IL139943A0 (bg)
NO (1) NO20006383D0 (bg)
NZ (1) NZ508532A (bg)
PL (1) PL345261A1 (bg)
SK (1) SK19192000A3 (bg)
WO (1) WO1999065491A1 (bg)
ZA (1) ZA200007396B (bg)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2418038A1 (en) * 2000-08-28 2002-03-07 Synthon B.V. Paroxetine compositions and processes for making the same
CA2471715A1 (en) 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
FR2926221A1 (fr) * 2008-01-14 2009-07-17 Tassin Thomas Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721723A (en) * 1985-10-25 1988-01-26 Beecham Group P.L.C. Anti-depressant crystalline paroxetine hydrochloride hemihydrate
US5371092A (en) * 1990-11-24 1994-12-06 Beecham Group, P.L.C. Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721723A (en) * 1985-10-25 1988-01-26 Beecham Group P.L.C. Anti-depressant crystalline paroxetine hydrochloride hemihydrate
US5371092A (en) * 1990-11-24 1994-12-06 Beecham Group, P.L.C. Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia

Also Published As

Publication number Publication date
NO20006383L (no) 2000-12-14
BG105127A (bg) 2001-11-30
AP2000002002A0 (en) 2000-12-31
GB9812941D0 (en) 1998-08-12
ZA200007396B (en) 2002-02-27
EP1087766A4 (en) 2001-11-21
CN1305379A (zh) 2001-07-25
PL345261A1 (en) 2001-12-03
JP2002518330A (ja) 2002-06-25
WO1999065491A1 (en) 1999-12-23
CZ20004698A3 (cs) 2002-02-13
EA200100041A1 (ru) 2001-06-25
NO20006383D0 (no) 2000-12-14
HUP0102507A2 (hu) 2002-05-29
IL139943A0 (en) 2002-02-10
BR9911150A (pt) 2001-03-06
EP1087766A1 (en) 2001-04-04
AU4688599A (en) 2000-01-05
CA2335236A1 (en) 1999-12-23
KR20010052895A (ko) 2001-06-25
HUP0102507A3 (en) 2003-12-29
EA003584B1 (ru) 2003-06-26
SK19192000A3 (sk) 2001-05-10
NZ508532A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
US6218421B1 (en) Method of promoting smoking cessation
KR101234940B1 (ko) 안정한 서방출형의 경구 투여용 조성물
CA2445678C (en) Paroxetine controlled release compositions
US6548084B2 (en) Controlled release compositions
TW550076B (en) Sustained release formulations
KR20090034372A (ko) 옥시코돈을 포함하는 과립 및 경구 붕해 정제
KR101858797B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
JP2002524416A (ja) 持続放出型ラノラジン製剤
US5814339A (en) Film coated tablet of paracetamol and domperidone
AU2012357956A1 (en) Immediate release multi unit pellet system
US6300343B1 (en) Method of treatment
AU2005204014B2 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
AU740749B2 (en) Method of treatment
AU2003224419A1 (en) Orally administrable pharmaceutical formulation
JP2000502066A (ja) 徐放性シサプリド
MXPA00012626A (en) Method of treatment
AU748804B2 (en) Paroxetine controlled release compositions
KR101199654B1 (ko) 안정한 서방출형의 경구 투여용 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)